AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03845517
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05560945
Drug: 1.5% Arginine Dentifrice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toothpaste
Trial: NCT01058291
Drug: KW-6500 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve weeks subcutaneous injection for the OFF state
Trial: NCT03103256
Drug: YHP1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily (QD), 8 weeks
Trial: NCT03103256
Drug: YHR1703
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily (QD), 8 weeks
Trial: NCT03103256
Drug: YHR1704
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PO, Once daily (QD), 8 weeks
Trial: NCT01450514
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
Trial: NCT02915172
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
Trial: NCT00640939
Drug: diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
Trial: NCT00640939
Drug: Matching Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
Trial: NCT00256932
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02748057
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01990573
Drug: 0.4mg/kg IV methadon HCl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group II will receive 0.4mg/kg IV methadone HCl.
Trial: NCT00115206
Drug: Neulasta® (pegfilgrastim)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03944863
Drug: Antibiotics
RxNorm normalized name: Antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04445090
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00905632
Drug: Placebo + SOC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tid +SOC
Trial: NCT04232644
Drug: ADAIR 10mg IR capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Description: manipulated ADAIR IR 3x10 mg capsules
Trial: NCT00161434
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo for 8 weeks
Trial: NCT00741689
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
Trial: NCT00758498
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablets, once daily in the morning for 3 days
Trial: NCT00308516
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Systemic Treatment:~leucovorin 350 mg prior to FU on days 1 and 15
Trial: NCT01229215
Drug: FCFD4514S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating intravitreal injection
Trial: NCT01229215
Drug: sham
RxNorm normalized name: SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeating sham injection
Trial: NCT04306497
Drug: TCM prescriptions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM prescriptions1:Take decocted or granule, one dose a day; TCM prescriptions2:Take decocted or granule, one dose a day.
Trial: NCT02982889
Drug: Diluent for LIQ865
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
Trial: NCT01951105
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Take one 250mg naproxen tablet three times a day for 12 weeks.
Trial: NCT00005959
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00005959
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02781818
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline 0.1 mL will be administered intralesionally at the selected site.
Trial: NCT03166501
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three 60 min parenteral infusions over a 5 day period
Trial: NCT01569945
Drug: Clomifen, Ethinyl Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
Trial: NCT00005916
Drug: rV-PSA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005916
Drug: rF-PSA
RxNorm normalized name: Aminosyn-RF 5.2 %, Sulfite-Free
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005916
Drug: rV-B7.1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01957579
Drug: MEDI-551
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
Trial: NCT02726789
Drug: REP 2139-Ca
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
Trial: NCT01589419
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: see arm description
Trial: NCT02554045
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
Trial: NCT02716792
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
Trial: NCT04331834
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with the following dosage:~* day 0: 400 mg (2 tablets)~* day 1: 400 mg (2 tablets)~* day 2: 400 mg (2 tablets)~* day 3: 400 mg (2 tablets)~* weekly: 400 mg (2 tablets) for a period of six months
Trial: NCT01951105
Drug: Carbidopa/Levodopa
RxNorm normalized name: CARBIDOPA/LEVODOPA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period.
Trial: NCT01951105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take two placebo capsules three times a day for 12 weeks.
Trial: NCT03234842
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent weekly chemotherapy at standard doses
Trial: NCT02261519
Drug: NaBen®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg twice daily (1000 mg total)
Trial: NCT00219635
Drug: UK-390,957
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02867332
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Trial: NCT03303521
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .~Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days.
Trial: NCT01725087
Drug: Medium Dose GRT6005
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03204617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20. At least 24 weeks since the fifth Placebo administration, 0.9% sterile normal saline solution at weeks 0, 12 and 24
Trial: NCT01898052
Drug: single anaesthetic drug
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inject periarticular tissue of the knee after implantation
Trial: NCT01898052
Drug: multimodal drug injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: inject periarticular tissue of the knee
Trial: NCT03905837
Drug: Remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous remifentanil
Trial: NCT01520207
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
Trial: NCT00112918
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Film-coated tablets
Trial: NCT00112918
Drug: Leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered as a 200 mg/m\^2 infusion over 2 hours.
Trial: NCT02964338
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to fremanezumab will be administered as per the schedule specified in the respective arms.
Trial: NCT01653457
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
Trial: NCT03952572
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750mg/m² ivgtt on day 1
Trial: NCT03952572
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40mg/m² ivgtt on day 1
Trial: NCT03952572
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50mg/m² ivgtt on day 1
Trial: NCT04037514
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous ibuprofen 10 mg/kg/24h (day 1) and 5 mg/kg/24h (day 2 and 3)
Trial: NCT02548052
Drug: GSK2981278 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
Trial: NCT02548052
Drug: Vehicle
RxNorm normalized name: Drug vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
Trial: NCT00237900
Drug: Gefitinib, 5-fluorouracil, leucovorin and radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04057937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01247350
Drug: LY3009104
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT01247350
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00122291
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00027885
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT00027885
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
Trial: NCT01007851
Drug: NaCl %0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml sterile saline sc injection 3 days after embryo transfer
Trial: NCT00003494
Drug: Antineoplaston therapy (Atengenal + Astugenal)
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with Recurrent or Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Trial: NCT05983328
Drug: HUYPS-1 nine tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 7-day washout time, subjects will receive HUYPS-1 9 tablets.
Trial: NCT01651416
Drug: Artemether-lumefantrine combination
RxNorm normalized name: ARTEMETHER/LUMEFANTRINE
DrugBank: Lumefantrine co-artemether (DB13085)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01896193
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet administered orally once daily
Trial: NCT01837251
Drug: PLD
RxNorm normalized name: PLD1
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02028507
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02633969
Drug: Indomethacin Capsules high dose
RxNorm normalized name: indomethacin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01750060
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02493452
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00837967
Drug: Symbicort Turbuhaler
RxNorm normalized name: Symbicort Turbuhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160/4.5μg for 3 days
Trial: NCT02446444
Drug: Conventional NSAA
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04718480
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: po placebo tablets
Trial: NCT00920959
Drug: FSC 100/50mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing
Trial: NCT00920959
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily dosing
Trial: NCT02716779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
Trial: NCT00941304
Drug: Placebo Film
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of placebo buccal film
Trial: NCT00941304
Drug: Placebo Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose of oral placebo capsule
Trial: NCT03311841
Drug: Atorvastatin and rosuvastatin oral solution
RxNorm normalized name: rosuvastatin and ezetimibe
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100/50 μg atorvastatin and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
Trial: NCT02992028
Drug: Intravenous Nutrition (Vitamins) injection
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02536105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01151345
Drug: TILACEM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
Trial: NCT03761134
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03761134
Drug: sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT00028626
Drug: embolization therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03249168
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet
Trial: NCT04044820
Drug: Standardized Prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 5mg PO q4-6h PRN~If patient has allergy or other contraindications~Hydromorphone 1mg PO q4-6h PRN/ Tylenol #3 1-2 tablets PO q4h PRN~The number of tablets prescribed will depend on the extent of surgical trauma~* 0-5 pills for simple surgeries such as a trigger finger release~* 10 pills for carpal tunnel or Dupuytren's contracture releases~* 15 pills for a ganglion cyst excision or simple tendon transfer~* 20 pills for more complex procedures such as distal forearm ORIF or a wrist fusion.
Trial: NCT00417157
Drug: recombinant FSH (Puregon, Organon, The Netherlands)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02574663
Drug: TGR-1202
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGR-1202 oral daily dose
Trial: NCT02574663
Drug: Oxaliplatin + Folinic acid + Fluorouracil
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT02627573
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00437996
Drug: Sufentanil
RxNorm normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04056949
Drug: IBI308
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IBI308 200mg IV infusion, every 3 weeks,until disease progress or intolerable toxicity,used up to 1 year (or 16 cycles)
Trial: NCT00139659
Drug: Inhaled Insulin
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
Trial: NCT00139659
Drug: Subcutaneous Insulin
RxNorm normalized name: subcutaneous insulin pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
Trial: NCT03215875
Drug: Fed- 60mg ER Torsemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60mg ER Torsemide will be given after high fat, high-calorie meal
Trial: NCT04441788
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered by oral inhalation
Trial: NCT00995722
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
Trial: NCT00441493
Drug: fluvastatin
RxNorm normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00752999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet, oral, twice-a-day
Trial: NCT03868098
Drug: Placebo ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo ointment (vehicle)
Trial: NCT00301912
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00910871
Drug: TMC207
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.